Widespread Recalls of Contaminated Valsartan
Valsartan, a drug belonging to a class of angiotensin receptor blockers (ARBs) which is used to treat high blood pressure and congestive heart failure, is undergoing wide-scale recalls after product from certain manufacturers was discovered to be contaminated with the chemical N-nitrosodimethylamine (NDMA). NDMA is a known carcinogen which is highly toxic, especially to the liver.
Not all products containing Valsartan are part of the recall. The FDA is continuing to evaluate Valsartan-containing products. The most current list of recalled products can be found here. Valsartan-containing products which are not part of the recall can be found here.
This reflects the most up to date information in the ongoing evaluation as of August 27, 2018. If you have been prescribed Valsartan and your medication is not found on the list of products NOT included in the recall, you should visit your pharmacy immediately. They may be able to exchange your recalled medication with one that has not been contaminated.
For ongoing updates, check the FDA’s Valsartan webpage.
Contaminated API Traced Back to Manufacturing Plants
Valsartan is an active pharmaceutical ingredient or API which is used by pharmaceutical companies to create finished drug products. The contaminated API’s have been traced back to three different manufacturers. Zhejiang Huahai Pharmaceuticals, in Linhai, China, Zhejiang Tianyu Pharmaceuticals in Taizhou, China, and Hetero Labs Limited, in India. Pharmaceutical companies who have sourced their Valsartan API from these plants are voluntarily recalling their contaminated products.
This toxic compound develops when certain manufacturing processes are used. Processes which these three plants share in common. The FDA is now investigating other manufacturers of the API who may be using similar processes, to determine if other plants may also be producing contaminated Valsartan.
According to both the CDC and the EPA, exposure to NDMA may cause cancer and liver toxicity. If you’ve been diagnosed with any type of cancer or liver complications after taking a drug containing contaminated Valsartan, you may be eligible for compensation.
While no verdicts or settlements have yet been issued, damages for which plaintiffs may be compensated could include the cost of treatment for illness, time lost from work, decreased quality of life, and pain and suffering. Those involved in lawsuits against manufacturers of Valsartan may also be eligible to receive punitive damages if a court finds the manufacturers negligence to have been especially egregious.
Marasco & Nesselbush Represent Victims of Contaminated Valsartan
If you’ve been prescribed one of the recalled drugs and think you may have been negatively affected by exposure to NDMA, our firm wants to help you. You may be able to recover substantial damages in a personal or class action lawsuit. We are offering free case evaluations and would love to see if we can help you. Call us to set up a free consultation at (401) 443-2999.